Compare DexCom, Inc. (DXCM) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? DexCom, Inc. trades at $77.92 (market cap $28.06B), while Vanguard Short Term Corporate Bond ETF trades at $78.73. The key difference: DexCom, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | VCSH | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Fixed Income |
52-Week High | $89.53 | $80.20 |
52-Week Low | $54.84 | $78.45 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
VCSH trades at $78.705, up 0.13% on the day, with a bearish technical signal from moving averages but neutral oscillators. The ETF focuses on short-term investment-grade corporate bonds, offering monthly dividends and a low expense ratio. Recent news highlights its higher yield compared to similar funds, with institutional investors adjusting positions amid a stable rate environment.
Outlook remains stable with consistent income appeal, though bearish technicals and Fed rate uncertainty pose near-term risks. The ETF's low-cost structure and credit quality support defensive positioning, but interest rate sensitivity and economic shifts could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
